Journal
JOURNAL OF HEMATOLOGY & ONCOLOGY
Volume 6, Issue -, Pages -Publisher
BMC
DOI: 10.1186/1756-8722-6-1
Keywords
FCGR2A; FCGR3A; trastuzumab; rituximab; cetuximab; ADCC
Categories
Funding
- Peter MacCallum Cancer Foundation
- National Breast Cancer Foundation (Australia)
Ask authors/readers for more resources
Antibody-dependent cellular cytotoxicity (ADCC) is a major mechanism of action of therapeutic monoclonal antibodies (mAbs) such as cetuximab, rituximab and trastuzumab. Fc gamma receptors (FcgR) on human white blood cells are an integral part of the ADCC pathway. Differential response to therapeutic mAbs has been reported to correlate with specific polymorphisms in two of these genes: FCGR2A (H131R) and FCGR3A (V158F). These polymorphisms are associated with differential affinity of the receptors for mAbs. This review critically examines the current evidence for genotyping the corresponding single nucleotide polymorphisms (SNPs) to predict response to mAbs in patients with cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available